B3GALT1
Basic information
Region (hg38): 2:167293001-167874045
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the B3GALT1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 13 | 14 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 13 | 1 | 0 |
Variants in B3GALT1
This is a list of pathogenic ClinVar variants found in the B3GALT1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-167869112-A-G | not specified | Likely benign (Feb 02, 2022) | ||
2-167869124-A-C | not specified | Uncertain significance (May 24, 2024) | ||
2-167869130-T-C | not specified | Uncertain significance (Feb 27, 2023) | ||
2-167869160-C-A | not specified | Uncertain significance (Jan 05, 2022) | ||
2-167869160-C-G | not specified | Uncertain significance (Jan 31, 2022) | ||
2-167869203-C-G | not specified | Uncertain significance (Sep 01, 2021) | ||
2-167869214-A-T | not specified | Uncertain significance (Oct 02, 2023) | ||
2-167869337-A-T | not specified | Uncertain significance (Oct 03, 2023) | ||
2-167869388-C-T | not specified | Uncertain significance (Aug 16, 2021) | ||
2-167869409-C-T | not specified | Uncertain significance (Jan 26, 2023) | ||
2-167869427-G-T | not specified | Uncertain significance (Jun 16, 2023) | ||
2-167869577-AT-A | Malignant tumor of prostate | Uncertain significance (-) | ||
2-167869592-G-A | not specified | Uncertain significance (Sep 17, 2021) | ||
2-167869626-C-T | not specified | Uncertain significance (Nov 03, 2023) | ||
2-167869658-G-A | not specified | Uncertain significance (Jan 19, 2024) | ||
2-167869896-A-G | Uncertain significance (Jun 02, 2020) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
B3GALT1 | protein_coding | protein_coding | ENST00000392690 | 1 | 55370 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0102 | 0.949 | 0 | 0 | 0 | 0 | 0.00 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.58 | 125 | 186 | 0.673 | 0.00000966 | 2173 |
Missense in Polyphen | 19 | 60.719 | 0.31292 | 722 | ||
Synonymous | -0.814 | 76 | 67.5 | 1.13 | 0.00000368 | 617 |
Loss of Function | 1.77 | 5 | 11.5 | 0.436 | 8.00e-7 | 121 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Beta-1,3-galactosyltransferase that transfers galactose from UDP-alpha-D-galactose to substrates with a terminal beta-N- acetylglucosamine (beta-GlcNAc) residue. Involved in the biosynthesis of the carbohydrate moieties of glycolipids and glycoproteins. Inactive towards substrates with terminal alpha-N- acetylglucosamine (alpha-GlcNAc) or alpha-N-acetylgalactosamine (alpha-GalNAc) residues. {ECO:0000269|PubMed:9582303}.;
- Pathway
- Glycosphingolipid biosynthesis - lacto and neolacto series - Homo sapiens (human);Ganglio Sphingolipid Metabolism;Metabolism of Spingolipids in ER and Golgi apparatus
(Consensus)
Recessive Scores
- pRec
- 0.149
Intolerance Scores
- loftool
- 0.290
- rvis_EVS
- -0.23
- rvis_percentile_EVS
- 37.11
Haploinsufficiency Scores
- pHI
- 0.211
- hipred
- Y
- hipred_score
- 0.605
- ghis
- 0.536
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.926
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- B3galt1
- Phenotype
Gene ontology
- Biological process
- protein glycosylation;protein N-linked glycosylation;galactosylceramide biosynthetic process;oligosaccharide biosynthetic process;lipid glycosylation
- Cellular component
- Golgi membrane;endoplasmic reticulum;Golgi apparatus;integral component of membrane
- Molecular function
- acetylgalactosaminyltransferase activity;UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase activity;glucosaminylgalactosylglucosylceramide beta-galactosyltransferase activity